Highlands Oncology Group

1. AstraZeneca Pharmaceuticals LP $6,812,631 38 payments
2. Novartis Pharmaceuticals Corporation $6,208,752 80 payments
3. Pfizer Inc. $2,448,802 326 payments
4. Array BioPharma Inc. $2,244,474 183 payments
5. Seattle Genetics, Inc. $793,789 206 payments
6. Genentech, Inc. $734,599 178 payments
7. AbbVie, Inc. $729,511 218 payments
8. Merck Sharp & Dohme Corporation $717,722 11 payments
9. Daiichi Sankyo Inc. $448,619 277 payments
10. Takeda Pharmaceuticals U.S.A., Inc. $320,630 28 payments

1. A Post-Trial Access Roll-Over Study to Allow Access to Ribociclib (Lee011) for Patients Who Are on Ribociclib Treatment in Novartis-Sponsored Study $3,424,147 7 payments
2. SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease $3,158,210 5 payments
3. A 2Part Phase III Randomized Open Label Multicenter Study of Lgx818 Plus Mek162 Versus Vemurafenib and Lgx818 Monotherapy in Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma $1,979,264 88 payments
4. A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) $993,164 2 payments
5. An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) $840,471 5 payments
6. Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) $746,058 5 payments
7. An Open Label Multi Center Ldk378 Roll Over Protocol for Patients Who Have Completed A Previous Novartis Sponsored Ldk378 Study and Are Judged By the Investigator to Benefit From Continued Ldk378 Treatment $685,417 6 payments
8. A Phase 1B2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab in Combination With the Polyadenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Locally Advanced Or Metastatic Solid Tumors $630,217 80 payments
9. A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) $584,217 4 payments
10. A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3) $473,846 3 payments

1. Non-patient care $54,172 34 payments
2. Patient care $22,850 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.